Targeting STAT3 Signaling for Immune Checkpoint Blockade to Augment PARP Inhibitor Therapy in BRCA-Mutated Ovarian Cancer PARP inhibitors and immune checkpoint inhibitors are two promising new therapies for ovarian cancer patients who have mutations in the BRCA gene. BRCA-mutated ovarian cancer cells produce a protein called PD-L1 to avoid being recognized and killed by immune […]
Read More
Jason Wilken, PhD, BSYale University Overcoming Primary Herceptin Resistance in Ovarian Cancer Herceptin, a therapeutic antibody that targets ErbB2 and has a well-tolerated safety profile has proven exceptionally useful as a treatment for ErbB2+ breast cancer patients. Surprisingly, Herceptin has proven to be ineffective as a treatment option for ovarian cancer. Dr. Wilken, with the […]
Read More
Yang Yang-Hartwich, PhDYale University2015 Cookie Laughlin Bridge Funding Award Targeting p53-regulated Twist1 Degradation to Inhibit Ovarian Cancer Metastasis Metastasis is a hallmark of advanced high-grade serous ovarian carcinoma. Turning off the ability of ovarian cancer to spread or metastasize to other places in the body would provide better therapies and prevent recurrence. The objective of […]
Read More
Jason Wilken, PhDYale University sErb83: A novel ovarian cancer prognostic biomarker A well-studied growth regulator in the development of ovarian cancer is the “oncogene” known as ErbB3/HER-3. There are several naturally-occurring variants of ErbB3 which are difficult to distinguish by currently available methods. We believe that developing accurate and specific tests for each ErbB3 variant […]
Read More